JAPANESE COHORT STUDY OF FIRST LINE CHEMOTHERAPY (CT) FOR METASTATIC COLORECTAL CANCER (MCRC) CONTAINING FLUOROPYRIMIDINE, OXALIPLATIN AND BEVACIZUMAB: EMERALD STUDY, FIRST REPORT

被引：0
|
作者：
Taku, K. [1 ]
Ohata, K. [1 ]
Yamazaki, K. [2 ]
Nishikawa, G. [1 ]
Watanabe, M. [3 ]
Sato, S. [3 ]
Oshima, T. [3 ]
Hirano, H. [1 ]
Amano, T. [4 ]
Ohashi, Y. [5 ]
机构：
[1] Shizuoka Prefectural Gen Hosp, Div Med Oncol, Shizuoka, Japan
[2] Shizuoka Canc Ctr, Shizuoka, Japan
[3] Shizuoka Prefectural Gen Hosp, Div Surg, Shizuoka, Japan
[4] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan
[5] Univ Tokyo, Sch Publ Hlth, Dept Biostat, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：220 / 220
页数：1
相关论文
共 50 条
  • [31] Phase I/II Study of Capecitabine Plus Oxaliplatin (XELOX) Plus Bevacizumab As First-line Therapy in Japanese Patients with Metastatic Colorectal Cancer
    Doi, Toshihiko
    Boku, Narikazu
    Kato, Ken
    Komatsu, Yoshito
    Yamaguchi, Kensei
    Muro, Kei
    Hamamoto, Yasuo
    Sato, Atsushi
    Koizumi, Wasaburo
    Mizunuma, Nobuyuki
    Takiuchi, Hiroya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (10) : 913 - 920
  • [32] ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK
    Khakoo, Shelize
    Chau, Ian
    Pedley, Ian
    Ellis, Richard
    Steward, Will
    Harrison, Mark
    Baijal, Shobhit
    Tahir, Saad
    Ross, Paul
    Raouf, Sherif
    Ograbek, Agnes
    Cunningham, David
    CLINICAL COLORECTAL CANCER, 2019, 18 (04) : 280 - +
  • [33] Phase I/II study of capecitabine(C)/oxaliplatin(O)/ irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
    Ou, K.
    Liu, X.
    Ma, X.
    Gao, L.
    Wang, Q.
    Yang, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S1514 - S1514
  • [34] The study of efficacy and safety of chemotherapy plus bevacizumab with oxaliplatin stop-and-go strategy in first-line treatment for metastatic colorectal cancer.
    Takano, Nao
    Nakayama, Goro
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [35] Surgery with curative intent in patients (pts) treated with first-line chemotherapy (CT) plus bevacizumab (BEV) for metastatic colorectal cancer (mCRC): First BEAT and NO16966
    Cassidy, J.
    Cunningham, D.
    Berry, S. R.
    Rivera, F.
    Clarke, S. J.
    Kretzschmar, A.
    Diaz-Rubio, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] EFFECTIVENESS OF CHEMOTHERAPY WITH OXALIPLATIN, CAPECITABINE AND BEVACIZUMAB (XELOX plus BEV) IN SECOND LINE THERAPY OF METASTATIC COLORECTAL CANCER (MCRC)
    Arzykulov, Z.
    Chichua, N.
    Smagulova, K.
    Khamidullina, G.
    Mukanova, S.
    Suriya, K.
    ANNALS OF ONCOLOGY, 2010, 21 : 32 - 32
  • [37] Safety analysis of first-line bevacizumab plus chemotherapy in patients with metastatic colorectal cancer (mCRC) participating in a US registry
    Kozloff, M.
    Cohn, A.
    Christiansen, N.
    Flynn, P.
    Kabbinavar, F.
    Robles, R.
    Ulcickas-Yood, M.
    Sarkar, S.
    Hambleton, J.
    Grothey, A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 173 - 173
  • [38] MULTICENTER PHASE II STUDY OF BEVACIZUMAB, OXALIPLATIN AND CAPECITABINE AS FIRST-LINE CHEMOTHERAPY IN METASTATIC COLORECTAL CANCERS: KOREA CANCER STUDY GROUP TRIAL: PRELIMINARY DATA
    Lee, S. S.
    Kim, T. W.
    Ahn, J. B.
    Jung, K. H.
    Im, S.
    Kim, J. H.
    Park, Y. S.
    ANNALS OF ONCOLOGY, 2008, 19 : 146 - 146
  • [39] Safety of bevacizumab with fluoropyrimidine-based regimens for first-line teatment of metastatic colorectal cancer
    Tyagi, Preeta
    Chu, Edward
    CLINICAL COLORECTAL CANCER, 2006, 6 (03) : 189 - 191
  • [40] A phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidine, oxaliplatin, and bevacizumab
    Nakajima, Go
    Kuramochi, Hidekazu
    Ando, Masayuki
    Itabashi, Michio
    Kawakami, Kazuyuki
    Hamano, Mie
    Hirai, Eiichi
    Lino, Takayuki
    Yokomizo, Hajime
    Okuyama, Ryuji
    Araida, Tatsuo
    Yoshimatsu, Kazuhiko
    Kameoka, Shingo
    Hayashi, Kazuhiko
    CANCER RESEARCH, 2016, 76
12345